Compare FTEL & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEL | EVGN |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | Australia | Israel |
| Employees | N/A | N/A |
| Industry | | Agricultural Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.9M |
| IPO Year | 2023 | N/A |
| Metric | FTEL | EVGN |
|---|---|---|
| Price | $0.70 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | ★ 11.1M | 47.7K |
| Earning Date | 11-17-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,200,138.00 | ★ $8,016,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.42 | 7.19 |
| 52 Week Low | $0.62 | $0.95 |
| 52 Week High | $792.00 | $2.42 |
| Indicator | FTEL | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 43.17 |
| Support Level | $0.69 | $1.07 |
| Resistance Level | $2.00 | $1.19 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 3.49 | 30.77 |
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.